Title |
Updating the OMERACT filter: implications for patient-reported outcomes.
|
---|---|
Published in |
Journal of Rheumatology, March 2014
|
DOI | 10.3899/jrheum.131312 |
Pubmed ID | |
Authors |
John R Kirwan, Susan J Bartlett, Dorcas E Beaton, Maarten Boers, Ailsa Bosworth, Peter M Brooks, Ernest Choy, Maarten de Wit, Francis Guillemin, Sarah Hewlett, Tore K Kvien, Robert B Landewé, Amye L Leong, Anne Lyddiatt, Lyn March, James May, Pamela Lesley Montie, Enkeleida Nikaï, Pam Richards, Marieke M J H Voshaar, Wilma Smeets, Vibeke Strand, Peter Tugwell, Laure Gossec |
Abstract |
At a previous Outcome Measures in Rheumatology (OMERACT) meeting, participants reflected on the underlying methods of patient-reported outcome (PRO) instrument development. The participants requested proposals for more explicit instrument development protocols that would contribute to an enhanced version of the "Truth" statement in the OMERACT Filter, a widely used guide for outcome validation. In the present OMERACT session, we explored to what extent these new Filter 2.0 proposals were practicable, feasible, and already being applied. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | 50% |
United States | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 73 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 15 | 21% |
Researcher | 12 | 16% |
Student > Doctoral Student | 9 | 12% |
Student > Master | 6 | 8% |
Student > Bachelor | 4 | 5% |
Other | 12 | 16% |
Unknown | 15 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 30 | 41% |
Nursing and Health Professions | 6 | 8% |
Social Sciences | 3 | 4% |
Biochemistry, Genetics and Molecular Biology | 2 | 3% |
Business, Management and Accounting | 2 | 3% |
Other | 9 | 12% |
Unknown | 21 | 29% |